Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15p -0.60% 24.85p 364,474 16:35:06
Bid Price Offer Price High Price Low Price Open Price
24.25p 25.45p 25.45p 24.00p 24.30p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -33.16 -14.07 73.7

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Share Charts

1 Year Motif Bio Chart

1 Year Motif Bio Chart

1 Month Motif Bio Chart

1 Month Motif Bio Chart

Intraday Motif Bio Chart

Intraday Motif Bio Chart

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:29:4924.3770,00017,059.14O
16:20:1524.253,917949.87AT
16:19:5624.851,987493.77O
16:04:2924.3725,0006,092.55O
15:49:5024.9533,0098,235.75O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
18/12/2018
08:20
Motif Bio Daily Update: Motif Bio is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 25p.
Motif Bio has a 4 week average price of 24p and a 12 week average price of 24p.
The 1 year high share price is 43.50p while the 1 year low share price is currently 24p.
There are currently 296,660,243 shares in issue and the average daily traded volume is 331,859 shares. The market capitalisation of Motif Bio is £75,500,031.84.
27/11/2018
08:12
uncleoswald: The share graph does not look good. With 3 months to go til approval by the FDA for a new antibiotic, you would expect the share price to be hitting new highs. Instead, it is hitting new lows. Conclusion you have to draw is someone knows it is not going to get approval. Can’t think of any other logical reason. If that is the case, price will continue dropping!
09/11/2018
14:59
spmc: For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
14/8/2018
06:50
t-trader: Great news...hopefully see the share price higher as we near next year
09/8/2018
02:41
mirako: Worth noting the FDA advisory committee's positive vote for Omadacycline in the treatment of ABSSSI. hTTps://finance.yahoo.com/news/fda-advisory-committee-recommends-approval-182008050.html The share price performance for Paratek is not exactly encouraging. The market seems to have doubts about new antibiotics.
23/5/2018
06:46
t-trader: This is good news, at least we don't have to worry about AMP dumping shares on the open market which indeed would have been a major drag on the share price. Selling to a US investor should give us a much needed lift.
21/5/2018
12:22
rizler: Except for the share price itself...
17/5/2018
10:32
gclark: with a book building mtfb are offering the minimum number of shares to people that will raise the amount required, letting them say how much they would pay for each share, so they tender for shares, and if they are too low and shares can be sold at a higher price to raise the £10m, they get zilch all shares are sold at the same price, so the final price is the maximum share price that raises the money required I think it will be a minimum of 32p, I expect more, I can imagine the stage of this company will be attractive to big investors and they may realise they need to pay more at this stage, and maybe not any more opportunities to buy in bulk before approval two big investors recently paid in the 40s for shares if I was bidding I would offer 36p for £1m worth of shares, but I'm not!
14/5/2018
13:04
spmc: For any one who's interested in some easy profit trial results for Evgen Pharma are expected on Wednesday. They have three presentations lined up the first one on the 16 May 2018 and the trial results are expected to be announced the morning before the first presentation. Broker Northland expects SFX-01 to meet the safety and efficacy endpoints for both trials and have a price target of 113p that's 6.5 times the current share price. So results due Wednesday and expected to be positive and it should at least triple from these low levels on good results, it's a screaming buy. Only today and tomorrow left to get in. Going to move some more of my holdings from here and move them back on Thursday.
04/10/2017
17:22
gersemi: Motif Bio : The home plate beckons 13:15 04 Oct 2017 US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land. Antibiotics INVESTMENT OVERVIEW: MTFB The Big Picture Patients are increasingly showing resistance to the effects of competing antibiotic vancomycin Motif Bio Plc (LON:MTFB) on Wednesday came a step closer to crossing home plate with its lead product, a next-generation antibiotic called iclaprim. For the early results of second phase III clinical study, called REVIVE-2, revealed the medication was both effective and well tolerated. Northland Capital’s Vadim Alexandre said the company had passed its biggest milestone to date, putting it on course to make a new drug submission in the first quarter next year. If all goes to plan, the market launch of iclaprim, which is also being developed for other indications such as hospital acquired infections, should take place in the second half of 2018. The shares shot up 41% to 51.69p, valuing Motif at £136mln. But that might not capture the full potential of Motif’s breakthrough. Northland’s Alexandre pointed out that when benchmarking Motif it might be worth using as a reference Paratek Pharmaceuticals, which is listed on NASDAQ and has a drug similar to iclaprim coming to market. The Americans, who tend to be a little punchier with their valuations, think it is worth US$700mln, or £527mln. The small-cap broker, finnCap, certainly thinks there’s some upside to the current share price with its £1 a share price target, which would get Motif to the quarter of a billion pound mark We’ll have to wait to see if there is a re-rating and just how far into the stratosphere this takes us, but all the ingredients are there. So what exactly has happened? Well we received what is called top-line data from the REVIVE-2 trial – that’s the bare-bones result from a months’ long study. The trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI). The intent was to show that iclaprim was just as good as (the technical term is non-inferior to) the gold standard medication. The results did just that. Chief executive Graham Lumsden said the positive outcome was “testament to the incredible efforts of our team at Motif who have worked tirelessly to get us to this stage”. “We believe that these results validate our belief in iclaprim as a potential new antibiotic candidate for patients with serious and life-threatening infections. I thank the patients and clinicians who participated in this important study,” he added. Valuable asset If approved, the antibiotic will be an important new option for patients with ABSSSI, especially those who may also have kidney disease. This could apply to just over a quarter of the 3.6mln people annually who contract the acute skin infection in the US. “Unlike current standard of care antibiotics, in clinical trials to date, kidney toxicity has not been observed with iclaprim and dosage adjustment has not been required in patients with renal impairment,” said Lumsden. “Iclaprim may be an important option for the growing population of patients with ABSSSI and kidney disease who need a safe and effective antibiotic targeting Gram-positive bacteria, including MRSA." As mentioned above, this wasn’t the first phase III assessment successfully completed by Motif. Potential partnerships? REVIVE-1 was an identical study, but used different trial centres. It also rubber stamped the potential of iclaprim in patients with ABSSSI. Results from the first cohort also revealed it as a potential alternative treatment for those with kidney disease, which could end up being a a huge selling point. “[There are] unique clinical benefits aimed at prescribing clinicians that will, in our opinion drive iclaprim adoption at an accelerated pace,” said finnCap analyst Alex Pye. “Fixed dosage and renal sparing make a very compelling prescribing argument for treating patients with iclaprim over vancomycin, which increasingly shows signs of developing resistance.” Pye pointed out that Motif may be approached by larger pharmaceuticals companies who would look to sell the new product through their established sales networks and hospital contacts. He said this could drive market share gains beyond the 15% being predicted by the market. The finnCap number cruncher is sticking with his £1 a share valuation – for the time being - as US Food & Drug administration approval is yet to be granted. “But given iclaprim’s fast track status and potential appeal to clinicians, we believe that the long term prospects of the antimicrobial are robust,” he added. - From Proeactivv
18/8/2015
09:53
regandharry5: Antibiotics in the news again, every time the over use of current antibiotics and how ineffiecent they are is raised the MTFB share price rises.
Motif Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181218 17:12:11